Determination of ciprofloxacin in plasma by micro-liquid chromatography-mass spectrometry: An adapted method for neonates

Biomedical Chromatography

Volumn 25, Issue 7, 2011, Pages 827-832

  Grondin, Christel ^a   Zhao, Wei ^a,b   Fakhoury, May ^a   Jacqz Aigrain, Evelyne ^a,b  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b INSERM   (France)

Author keywords

Ciprofloxacin; HPLC MS; Neonates; Population pharmacokinetics

Indexed keywords

ANTIBIOTICS; LIQUID CHROMATOGRAPHY; PHARMACOKINETICS;

ADAPTED METHODS; ANALYTICAL METHOD; CIPROFLOXACIN; HPLC-MS; LIQUID CHROMATOGRAPHY - MASS SPECTROMETRIES; MICRO-LIQUID CHROMATOGRAPHY; NEONATE; PHARMACOKINETIC STUDIES; POPULATION PHARMACOKINETICS; TECHNICAL ASPECTS;

MASS SPECTROMETRY;

CIPROFLOXACIN;

ACCURACY; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG MONITORING; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MICRO LIQUID CHROMATOGRAPHY; PEDIATRICS; PLASMA; PRECIPITATION; PROTEIN PRECIPITATION; SENSITIVITY AND SPECIFICITY;

EID: 79958205919     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1523     Document Type: Article

References (20)

1. Alghasham AA and Naahata MC. Clinical use of fluoroquinolones in children. The Annals of Pharmacotherapy 2000; 34: 347-359.
2. De Witte B, Dewulf J, Demeestere K, De Ruyck M and Van Langenhove H. Critical points in the analysis of ciprofloxacin by high-performance liquid chromatography. Journal of Chromatography A 2007; 1140: 126-130.
3. Fiel SB. Clinical management of pulmonary disease in cystic fibrosis. Lancet 1993; 341: 1070-1074.
4. Garcés A, Zerzanová A, Kucera R, Barrón D and Barbosa J. Determination of a series of quinolones in pig plasma using solid-phase extraction and liquid chromatography coupled with mass spectrometric detection Application to pharmacokinetic studies. Journal of Chromatography A 2006; 1137: 22-29.
5. Gendrel D, Chalumeau M, Moulin F and Raymond J. Fluoroquinolones in paediatrics: a risk for the patient or for the community? The Lancet Infectious Diseases 2003; 3: 537-546.
6. FDA. Guidance for Industry: Bioanalytical Method Validation. Department of Health and Human Services, Food and Drug Administration, 2001; available from:
7. FDA. Guideline on the Investigation of Medical Products in the Term and Preterm Neonate. European Medicines Agency Evaluation of Medicines for Human Use, 2010; available from:
8. Hoiby N. Microbiology of lung infection disease in cystic fibrosis patients. Acta Paediatrica Scandinavica 1982; 301: 33-54.
9. ICH. Topic Q2B Validation of Analytical Procedures: Methodology. The European Agency for the Evaluation of Medicinal Products, 1996; available from:
10. Idowu OR and Peggins JO. Simple, rapid determination of enrofloxacin and ciprofloxacin in bovine milk and plasma by high-performance liquid chromatography with fluorescence detection. Journal of Pharmaceutical and Biomedical Analysis 2004; 35: 143-153.
11. Imre S, Dogaru MT, Vari CE, Muntean T and Kelemen L. Validation of an HPLC method for the determination of ciprofloxacin in human plasma. Journal of Pharmaceutical and Biomedical Analysis 2003; 33: 125-130.
12. Kamberi M, Tsutsumi K, Kotegawa T, Nakamura K and Nakano S. Determination of ciprofloxacin in plasma and urine by HPLC with ultraviolet detection. Clinical Chemistry 1998; 44: 1251-1255.
13. Lee HB, Peart TE and Svoboda ML. Determination of ofloxacin, norfloxacin, and ciprofloxacin in sewage by selective solid-phase extraction, liquid chromatography with fluorescence detection, and liquid chromatography-tandem mass spectrometry. Journal of Chromatography A 2007; 1139: 45-52.
14. Lesne-Hulin A, Bourget P, Ravat F, Goudin C and Latarjet J. Clinical pharmacokinetics of ciprofloxacin in patients with major burns. European Journal of Clinical Pharmacology 1999; 55: 515-519.
15. Owens RC, Jr and Ambrose PG. Clinical use of the fluoroquinolones. The Medical Clinics of North America 2000; 84: 1447-1469.
16. Redmond A, Sweeney L, MacFarland M, Mitchell M, Daggett S and Kubin R. Oral ciprofloxacin in the treatment of paediatric cystic fibrosis: clinical efficacy and safety evaluation using magnetic resonance image scanning. Journal of International Medical Research 1998; 26: 304-312.
17. Tuerk J, Reinders M, Dreyer D, Kiffmeyer TK, Schmidt KG and Kuss HM. Analysis of antibiotics in urine and wipe samples from environmental and biological monitoring - comparison of HPLC with UV-, single MS- and tandem MS-detection. Journal of Chromatography B 2006; 831: 72-80.
18. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 1999; 58: 29-36.
19. Ward RM, Benitz WE, Benjamin DK Jr, Blackmon L, Giacoia GP, Hudak M, Lasky T, Rodriguez W and Selen A. Criteria supporting the study of drugs in the newborn. Clinical Therapeutics 2006; 28: 1385-1398.
20. Warren, RW. Rheumatologic aspects of pediatric cystic fibrosis patients treated with fluoroquinolones. The Pediatric Infectious Disease Journal 1997; 16: 118-122.